{"id":73962,"date":"2026-05-03T19:23:44","date_gmt":"2026-05-03T19:23:44","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/73962\/"},"modified":"2026-05-03T19:23:44","modified_gmt":"2026-05-03T19:23:44","slug":"novo-nordisk-rebrands-diabetes-pill-as-ozempic-to-compete-in-us-market-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/73962\/","title":{"rendered":"Novo Nordisk Rebrands Diabetes Pill as Ozempic to Compete in US Market, ETPharma"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/130717629.cms.jpeg\" captionrendered=\"1\" alt=\"\"\/><a id=\"26646230\" type=\"Denny\" weightage=\"20\" keywordseo=\"Novo-Nordisk\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/novo+nordisk\" rel=\"nofollow noopener\" target=\"_blank\">Novo Nordisk<\/a> is rebranding an existing, less-popular diabetes tablet as <a id=\"26542282\" type=\"Denny\" weightage=\"20\" keywordseo=\"Ozempic\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/ozempic\" rel=\"nofollow noopener\" target=\"_blank\">Ozempic<\/a> in the US in a bid to capitalize on the brand recognition of one of the world&#8217;s best-selling drugs.<\/p>\n<p>The Danish drugmaker will start selling <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/ozempic\" rel=\"nofollow noopener\" target=\"_blank\">Ozempic<\/a> pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday.<\/p>\n<p>Novo said the relaunched Ozempic pills are as safe and effective as tablets sold under the name <a id=\"30082219\" type=\"Denny\" weightage=\"20\" keywordseo=\"Rybelsus\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/rybelsus\" rel=\"nofollow noopener\" target=\"_blank\">Rybelsus<\/a>, which have the same main ingredient, <a id=\"26542283\" type=\"Denny\" weightage=\"20\" keywordseo=\"semaglutide\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/semaglutide\" rel=\"nofollow noopener\" target=\"_blank\">semaglutide<\/a>, but in a different formulation and set of doses. <a href=\"https:\/\/pharma.economictimes.indiatimes.com\/tag\/rybelsus\" rel=\"nofollow noopener\" target=\"_blank\">Rybelsus<\/a> will continue to be marketed outside the US.<\/p>\n<p>Novo is trying to win back market share from rival Eli Lilly &amp; Co., pinning its comeback on new formulations of its top-selling medicines and a more direct-to-consumer approach.<\/p>\n<p>A Wegovy pill introduced in January has had the strongest launch of any obesity drug to date, while Novo has also introduced a subscription program offering lower monthly prices for the drug.\n                                                                    <\/p>\n<p>                                    Published On May 2, 2026 at 07:06 PM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>                    All about ETPharma industry right on your smartphone! <\/p>\n<p>                        <img decoding=\"async\" loading=\"lazy\" width=\"90\" height=\"90\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/pharma_barcode.png\" alt=\"\"\/>                        <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to&hellip;\n","protected":false},"author":2,"featured_media":73963,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[20680,272,3102,15791,689],"class_list":{"0":"post-73962","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-diabetes-medication","9":"tag-novo-nordisk","10":"tag-ozempic","11":"tag-rybelsus","12":"tag-semaglutide"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116512280972751903","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/73962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=73962"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/73962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/73963"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=73962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=73962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=73962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}